# Dyanavel XR 20 mg improved simulated driving safety margins in young adults with ADHD

- Published: 2026-11-13 05:30 UTC
- Section: Life & Health › Medicine
- Tags: Dyanavel XR, extended-release amphetamine, ADHD in young adults, driving simulator, time to collision, braking intensity, randomized placebo-controlled trial, Advances in Therapy, MIT AgeLab
- URL: https://realtech.media/news/rt-8c2394e42e476c3caa7b7db6_dyanavel_xr_20/

**In a randomized placebo-controlled simulator study, young adults with ADHD kept a greater time to collision and braked less abruptly 10 h after a single amphetamine dose.**

![Dyanavel XR 20 mg improved simulated driving safety margins in young adults with ADHD](https://realtech.media/media/2026/11/d9d2da2a2d869e46.jpg)
*Ipareja, Wikimedia Commons, Public domain*

A randomized, double-blind, placebo-controlled study published in Advances in Therapy tested a single 20 mg tablet of extended-release amphetamine (Dyanavel XR, DXR) in young adults with clinically established attention-deficit/hyperactivity disorder (ADHD). Drivers aged 18-25 took simulated drives before the dose, 45 min after it and 10 h after it. The study was completed by 21 participants in the DXR group and 20 in the placebo group [1].

## Simulator design and endpoints

The single-center study measured safety-related parameters: proximity to a lead vehicle and braking response intensity across eight emergent conflict events per drive, each requiring an attentive response from the driver [1]. The authors describe the methodology as, to their belief, novel among intervention trials. An inattentive driver could come very close to the lead vehicle during a potential conflict, but the lead vehicle dynamics were adjusted so that the participant did not experience a simulated crash that could influence later behavior [1].

The key secondary endpoint was crash frequency during an event at the end of the third drive. That event did allow an inattentive driver to collide with the lead vehicle [1]. According to the publisher's summary, the tests were run in the MIT AgeLab simulator, with a passenger cabin on a motion platform, a divided two-lane highway with low-to-moderate traffic, no audio entertainment and no personal devices [1].

## Time to collision and braking

For DXR-treated participants with a complete evaluable data set (n = 17), the minimum time to collision and the mean highest braking intensity improved with statistical significance across their three drives [1]. In the comparison of the 45 min postdose drive with baseline, these changes appeared as a positive trend. In the comparison of the 10 h postdose drive with baseline, they reached statistically significant levels [1].

The authors conclude that participants who took a morning dose of DXR showed behavior during simulated driving consistent with improved safety-margin behavior (greater time to collision) and less abrupt braking at 10 h postdose. They limit this conclusion to the simulation context [1]. The trial is registered at ClinicalTrials.gov as NCT04027361 [1].

## Sources

1. [Advances in Therapy](https://doi.org/10.1007/s12325-026-03843-6)
2. [bioengineer.org](https://bioengineer.org/extended-release-amphetamine-improves-simulated-highway-driving-safety-margins-in-young-adult-adhd)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-8c2394e42e476c3caa7b7db6_dyanavel_xr_20/